Bharat Biotech

India’s first nasal covid-19 vaccine gets nod from DCGI

The DCGI approved Bharat Biotech's first intranasal Covid vaccine on Tuesday for use as the primary immunisation against the infection in adults above 18.

Japan lists Bharat Biotech’s Covaxin as recognized COVID-19 vaccine

The Indian Embassy in Japan informed the development on Twitter.

Bharat Biotech’s MD Krishna Ella & Joint MD Suchitra Ella awarded Padma Bhushan award

Padma Bhushan is awarded for the distinguished service of a high order.

FDA approves Bharat Biotech’s Covaxin for clinical trials in adults in US

Bharat Biotech and its US partner Ocugen said in a statement on Monday that they are committed to bringing Covaxin to the United States and Canada for all age groups.

CDSCO extends Covaxin’s shelf-life to 12 months from the date of manufacturing

The announcement comes just in time as the World Health Organisation has reportedly approved Bharat Biotech’s Covaxin for its Emergency Use Listing.

Cannot play with lives of people by ordering revaccination with Covishield without any data: SC

The top court was trying a petition that said that Covaxin was not recognised by the World Health Organisation (WHO). People here are encountering challenges in obtaining approval to travel overseas.

Covaxin approval delayed as WHO asks for additional data from Bharat Biotech

The TAG will now reconvene on November 3 for the final EUL assessment if the data asked of Bharat Biotech is provided by them soon. 

Bharat Biotech’s Covaxin gets approval for emergency use for children aged 2-18 years

Two doses of Covaxin are expected to be distributed to children with a gap of 28 days. The government has set an interval of 4-6 weeks for adults between the two shots.

Phase 2/3 trials of Bharat Biotech’s Chikungunya vaccine begins

Bharat Biotech’s COVAXIN to get WHO approval by August-end: Report

Bharat Biotech manufactured Covaxin most probable to be globally authorised by August-end, according to the latest reports by CNN News 18.

Brazil discards Covaxin’s application for emergency use

After the termination of MoU by Bharat Biotech, the Brazilian regulatory agency had announced its suspension of Phase 3 trials of Covaxin.

Government enhances steps for COVID-19 vaccines manufacturing in India

In the mission, clinical trial lot manufacturing of promising vaccine candidates which include the DNA vaccine candidate; ZydusCadila, mRNA vaccine candidate; Gennova Biopharmaceuticals, and Intanasal vaccine candidate; Bharat Biotech, were being supported.

Chief Scientist of WHO said Covaxin’s data looks good

She said that WHO would not recommend any booster shots anytime soon and the focus would remain on widening the scopes of primary vaccinations.

AIIMS Director says more data needed for mixing of COVID-19 vaccines

In the study, the researchers who were working to know the feasibility of using a different vaccine doss for the prime vaccination than the one used for the booster vaccination, discovered that mixing the doses of two different vaccines could generate stronger immunity.

India’s December-end target to vaccinate everyone requires Bharat Biotech to raise its game

India is counting on Bharat Biotech to supply a total of 48 crore doses of COVAXIN out of the 187 crore. It is needed to vaccinate all 93-94 crore adults in the country.